{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:41:16Z","timestamp":1794811276860,"version":"4.9.1"},"reference-count":100,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>\n                    The sodium-glucose cotransporter 2 (SGLT2) inhibitors have become an integral part of clinical practice guidelines to slow the progression of CKD in patients with and without diabetes mellitus. Although initially developed as antihyperglycemic drugs, their effect on the kidney is multifactorial resulting from profuse glycosuria and natriuresis consequent to their primary site of action. Hemodynamic and metabolic changes ensue that mediate kidney-protective effects, including (\n                    <jats:italic toggle=\"yes\">1<\/jats:italic>\n                    ) decreased workload of proximal tubular cells and prevention of aberrant increases in glycolysis, contributing to a decreased risk of AKI; (\n                    <jats:italic toggle=\"yes\">2<\/jats:italic>\n                    ) lowering of intraglomerular pressure by activating tubular glomerular feedback and reductions in BP and tissue sodium content; (\n                    <jats:italic toggle=\"yes\">3<\/jats:italic>\n                    ) initiation of nutrient-sensing pathways reminiscent of starvation activating ketogenesis, increased autophagy, and restoration of carbon flow through the mitochondria without production of reactive oxygen species; (\n                    <jats:italic toggle=\"yes\">4<\/jats:italic>\n                    ) body weight loss without a reduction in basal metabolic rate due to increases in nonshivering thermogenesis; and (\n                    <jats:italic toggle=\"yes\">5<\/jats:italic>\n                    ) favorable changes in quantity and characteristics of perirenal fat leading to decreased release of adipokines, which adversely affect the glomerular capillary and signal increased sympathetic outflow. Additionally, these drugs stimulate phosphate and magnesium reabsorption and increase uric acid excretion. Familiarity with kidney-specific mechanisms of action, potential changes in kidney function, and\/or alterations in electrolytes and volume status, which are induced by these widely prescribed drugs, will facilitate usage in the patients for whom they are indicated.\n                  <\/jats:p>","DOI":"10.2215\/cjn.09380822","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T13:45:11Z","timestamp":1665495911000},"page":"279-289","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":119,"title":["Kidney-Protective Effects of SGLT2 Inhibitors"],"prefix":"10.2215","volume":"18","author":[{"given":"Biff F.","family":"Palmer","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Clegg","sequence":"additional","affiliation":[{"name":"Internal Medicine, Texas Tech Health Sciences Center, El Paso, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"N Engl J Med"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice","volume":"292","author":"Wang","year":"2017","journal-title":"J Biol Chem"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/jcph.1030","article-title":"Model-based evaluation of proximal sodium reabsorption through sglt2 in health and diabetes and the effect of inhibition with canagliflozin","volume":"58","author":"Brady","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose co-transporters and their inhibition: Clinical physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis","volume":"1016","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: Asystematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcph.88","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","volume":"53","author":"Devineni","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves \u03b2-cell function","volume":"100","author":"Merovci","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc15-2688","article-title":"Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes","volume":"39","author":"Daniele","year":"2016","journal-title":"Diabetes Care"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","article-title":"Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: Results from the CREDENCE trial","volume":"141","author":"Cannon","year":"2020","journal-title":"Circulation"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"129034","DOI":"10.1172\/jci.insight.129034","article-title":"Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.diabet.2020.06.005","article-title":"Sodium-glucose cotransporter-2 inhibitors for diabetic kidney disease: Targeting Warburg effects in proximal tubular cells","volume":"46","author":"Morita","year":"2020","journal-title":"Diabetes Metab"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"22078","DOI":"10.1096\/fj.202100909RR","article-title":"SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney","volume":"36","author":"Ke","year":"2022","journal-title":"FASEB J"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJM199106063242304","article-title":"Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus","volume":"324","author":"Tuttle","year":"1991","journal-title":"N Engl J Med"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1523-1755.2004.00911.x","article-title":"Role of macula densa adenosine triphosphate (ATP) in tubuloglomerular feedback","volume":"66","author":"Ren","year":"2004","journal-title":"Kidney Int"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.kint.2021.10.037","article-title":"Role of the macula densa sodium glucose cotransporter type 1-neuronal nitric oxide synthase-tubuloglomerular feedback pathway in diabetic hyperfiltration","volume":"101","author":"Zhang","year":"2022","journal-title":"Kidney Int"},{"key":"B21-20241015","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1681\/ASN.2018080844","article-title":"Macula densa SGLT1-NOS1-tubuloglomerular feedback pathway, a new mechanism for glomerular hyperfiltration during hyperglycemia","volume":"30","author":"Zhang","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"Skrti\u0107","year":"2014","journal-title":"Diabetologia"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"F184","DOI":"10.1152\/ajprenal.00043.2017","article-title":"Urinary adenosine excretion in type 1 diabetes","volume":"313","author":"Rajasekeran","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/physrev.00031.2005","article-title":"Adenosine and kidney function","volume":"86","author":"Vallon","year":"2006","journal-title":"Physiol Rev"},{"key":"B27-20241015","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.122.059150","article-title":"Renal and vascular effects of combined SGLT2 and angiotensin-converting enzyme inhibition","volume":"146","author":"Lytvyn","year":"2022","journal-title":"Circulation"},{"key":"B28-20241015","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","article-title":"Glomerular hyperfiltration in experimental diabetes mellitus: Potential role of tubular reabsorption","volume":"10","author":"Vallon","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"B29-20241015","doi-asserted-by":"crossref","first-page":"F819","DOI":"10.1152\/ajprenal.00497.2016","article-title":"Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: A modeling analysis","volume":"312","author":"Hallow","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"B30-20241015","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.34067\/KID.0001172021","article-title":"eGFR decline after SGLT2 inhibitor initiation: The tortoise and the hare reimagined","volume":"2","author":"Meraz-Mu\u00f1oz","year":"2021","journal-title":"Kidney360"},{"key":"B31-20241015","doi-asserted-by":"crossref","first-page":"550","DOI":"10.34067\/KID.0007882021","article-title":"Drug-induced osmotic nephropathy: Add SGLT2-inhibitors to the list?","volume":"3","author":"Perazella","year":"2021","journal-title":"Kidney360"},{"key":"B32-20241015","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMra020676","article-title":"Renal dysfunction complicating the treatment of hypertension","volume":"347","author":"Palmer","year":"2002","journal-title":"N Engl J Med"},{"key":"B33-20241015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B34-20241015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-019-0920-4","article-title":"Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): More than osmotic diuresis","volume":"21","author":"Sternlicht","year":"2019","journal-title":"Curr Hypertens Rep"},{"key":"B35-20241015","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2013060588","article-title":"Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule","volume":"25","author":"Pessoa","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B36-20241015","doi-asserted-by":"crossref","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na+\/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"B37-20241015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1681\/ASN.2015111282","article-title":"MAP17 is a necessary activator of renal Na+\/glucose cotransporter SGLT2","volume":"28","author":"Coady","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B38-20241015","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/HJH.0000000000000871","article-title":"Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome","volume":"34","author":"Rahman","year":"2016","journal-title":"J Hypertens"},{"key":"B39-20241015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"B40-20241015","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1681\/ASN.2016060662","article-title":"Skin sodium concentration correlates with left ventricular hypertrophy in CKD","volume":"28","author":"Schneider","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B41-20241015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12933-017-0654-z","article-title":"SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: A randomised controlled trial","volume":"17","author":"Karg","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 1","key":"B42-20241015","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0735-1097(20)31702-2","article-title":"The Sglt2 inhibitor empagliflozin causes a greater reduction in skin sodium content and interstitial volume than loop diuretics in heart failure","volume":"75","author":"Santos-Gallego","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B43-20241015","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J Hypertens"},{"key":"B44-20241015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor-induced sympathoinhibition: A novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"B45-20241015","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1007\/s00125-020-05145-0","article-title":"Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes","volume":"63","author":"Gueguen","year":"2020","journal-title":"Diabetologia"},{"key":"B46-20241015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"B47-20241015","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"B48-20241015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40261-017-0580-6","article-title":"Clinical factors associated with initial decrease in body-fat percentage induced by add-on sodium-glucose co-transporter 2 inhibitors in patient with type 2 diabetes mellitus","volume":"38","author":"Kurinami","year":"2018","journal-title":"Clin Drug Investig"},{"key":"B49-20241015","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B50-20241015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"B51-20241015","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/biomedicines8110514","article-title":"SGLT2 inhibitor-induced sympathoexcitation in white adipose tissue: A novel mechanism for beiging","volume":"8","author":"Matthews","year":"2020","journal-title":"Biomedicines"},{"key":"B52-20241015","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"B53-20241015","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy balance after sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"key":"B54-20241015","doi-asserted-by":"crossref","first-page":"123130","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"B55-20241015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s11255-014-0656-7","article-title":"Perirenal fat associated with microalbuminuria in obese rats","volume":"46","author":"Hou","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"B56-20241015","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.2337\/db20-1031","article-title":"Perirenal fat thickness is significantly associated with the risk for development of chronic kidney disease in patients with diabetes","volume":"70","author":"Chen","year":"2021","journal-title":"Diabetes"},{"key":"B57-20241015","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/jch.13366","article-title":"Para-perirenal distribution of body fat is associated with reduced glomerular filtration rate regardless of other indices of adiposity in hypertensive patients","volume":"20","author":"Geraci","year":"2018","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B58-20241015","doi-asserted-by":"crossref","first-page":"7329","DOI":"10.3390\/ijms22147329","article-title":"Ipragliflozin ameliorates diabetic nephropathy associated with perirenal adipose expansion in mice","volume":"22","author":"Okuma","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B59-20241015","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1523-1755.1999.00626.x","article-title":"Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: Potential role in glomerulosclerosis","volume":"56","author":"Wolf","year":"1999","journal-title":"Kidney Int"},{"key":"B60-20241015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3940(00)01490-7","article-title":"Leptin injection into white adipose tissue elevates renal sympathetic nerve activity dose-dependently through the afferent nerves pathway in rats","volume":"293","author":"Tanida","year":"2000","journal-title":"Neurosci Lett"},{"key":"B61-20241015","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1038\/s41467-022-30868-6","article-title":"Perirenal adipose afferent nerves sustain pathological high blood pressure in rats","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"B62-20241015","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.mayocp.2022.01.012","article-title":"Metabolic flexibility and its impact on health outcomes","volume":"97","author":"Palmer","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"B63-20241015","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.2215\/CJN.17621120","article-title":"Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy","volume":"16","author":"Palmer","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B64-20241015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000517305","article-title":"Starvation ketosis and the kidney","volume":"52","author":"Palmer","year":"2021","journal-title":"Am J Nephrol"},{"key":"B65-20241015","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"B66-20241015","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.crphys.2022.05.003","article-title":"Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6\/J mice","volume":"5","author":"Xie","year":"2022","journal-title":"Curr Res Physiol"},{"key":"B67-20241015","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2337\/dc20-2887","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on energy metabolism in patients with type 2 diabetes: A randomized, double-blind crossover trial","volume":"44","author":"Op den Kamp","year":"2021","journal-title":"Diabetes Care"},{"key":"B68-20241015","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/EJE-17-0832","article-title":"MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?","volume":"178","author":"Esterline","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B69-20241015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000506534","article-title":"Mitigation of the adverse consequences of nutrient excess on the kidney: A unified hypothesis to explain the renoprotective effects of sodium-glucose cotransporter 2 inhibitors","volume":"51","author":"Packer","year":"2020","journal-title":"Am J Nephrol"},{"key":"B70-20241015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"B71-20241015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/obr.12563","article-title":"Non-shivering thermogenesis as a mechanism to facilitate sustainable weight loss","volume":"18","author":"Palmer","year":"2017","journal-title":"Obes Rev"},{"key":"B72-20241015","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","article-title":"SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition","volume":"32","author":"Tomita","year":"2020","journal-title":"Cell Metab"},{"key":"B73-20241015","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1172\/JCI44771","article-title":"mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice","volume":"121","author":"Inoki","year":"2011","journal-title":"J Clin Invest"},{"key":"B74-20241015","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","article-title":"Ketosis ameliorates renal cyst growth in polycystic kidney disease","volume":"30","author":"Torres","year":"2019","journal-title":"Cell Metab"},{"key":"B75-20241015","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B76-20241015","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B77-20241015","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease","volume":"21","author":"Maruyama","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"B78-20241015","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"B79-20241015","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: Modulation by SGLT2 inhibitors and hypoxia mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B80-20241015","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: A meta-analysis of randomised controlled trials","volume":"59","author":"Tang","year":"2016","journal-title":"Diabetologia"},{"key":"B81-20241015","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00581632","article-title":"Effect of glucagon on magnesium renal reabsorption in the rat","volume":"392","author":"Bailly","year":"1982","journal-title":"Pflugers Arch"},{"key":"B82-20241015","doi-asserted-by":"crossref","first-page":"F1386","DOI":"10.1152\/ajprenal.00593.2013","article-title":"Downregulation of transient receptor potential M6 channels as a cause of hypermagnesiuric hypomagnesemia in obese type 2 diabetic rats","volume":"308","author":"Takayanagi","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"B83-20241015","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.3390\/nu13114088","article-title":"Effect of dapagliflozin and magnesium supplementation on renal magnesium handling and magnesium homeostasis in metabolic syndrome","volume":"13","author":"Ng","year":"2021","journal-title":"Nutrients"},{"key":"B84-20241015","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1185\/03007995.2014.919907","article-title":"Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)","volume":"30","author":"Weir","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"B85-20241015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B86-20241015","doi-asserted-by":"crossref","first-page":"991123","DOI":"10.1172\/jci.insight.99123","article-title":"Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study","volume":"3","author":"Blau","year":"2018","journal-title":"JCI Insight"},{"key":"B87-20241015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MNH.0000000000000505","article-title":"Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus","volume":"28","author":"Vinke","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B88-20241015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B89-20241015","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2215\/CJN.16171221","article-title":"Fracture risk of sodium-glucose cotransporter-2 inhibitors in chronic kidney disease","volume":"17","author":"Cowan","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B90-20241015","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1172\/JCI110514","article-title":"Magnesium transport in the cortical thick ascending limb of Henle\u2019s loop of the rabbit","volume":"69","author":"Shareghi","year":"1982","journal-title":"J Clin Invest"},{"key":"B91-20241015","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1073\/pnas.1616733114","article-title":"Parathyroid hormone controls paracellular Ca2+ transport in the thick ascending limb by regulating the tight-junction protein Claudin14","volume":"114","author":"Sato","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B92-20241015","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/emboj.2012.49","article-title":"Claudin-14 regulates renal Ca++ transport in response to CaSR signalling via a novel microRNA pathway","volume":"31","author":"Gong","year":"2012","journal-title":"EMBO J"},{"key":"B93-20241015","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1681\/ASN.2021010042","article-title":"Molecular mechanisms of renal magnesium reabsorption","volume":"32","author":"Ellison","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B94-20241015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"B95-20241015","doi-asserted-by":"crossref","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","article-title":"SGLT2 inhibition and renal urate excretion: Role of luminal glucose, GLUT9, and URAT1","volume":"316","author":"Novikov","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"B96-20241015","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B97-20241015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S2665-9913(19)30078-5","article-title":"The effects of canagliflozin on gout in type 2 diabetes: A post-hoc analysis of the CANVAS Program","volume":"1","author":"Li","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"B98-20241015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/M19-2610","article-title":"Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"key":"B99-20241015","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2215\/CJN.02130221","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk of abnormal serum potassium level","volume":"16","author":"Hwang","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B100-20241015","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: A meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.09380822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:52Z","timestamp":1786369492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.09380822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.09380822","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}